Navigation Links
ARIUS 2008 Annual and Special Meeting of Shareholders
Date:4/9/2008

TORONTO, April 9 /PRNewswire-FirstCall/ - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, Annual and Special Meeting of Shareholders will be held:

Where: St. Andrew's Club & Conference Centre, S7 Caledonia Room,

150 King Street West, 27th Floor, Toronto, Ontario

When: Thursday, April 10th, 2008 at 10:00 a.m.

Webcast: ARIUS Research Inc.'s Annual and Special Meeting will be webcast

in real time. The webcast can be viewed online starting at

10:00 a.m. at http://www.ariusmabs.com, and will be archived for 12

months.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com.

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.


'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):